Lorlatinib Medication Information

Get detailed information on Lorlatinib, including pronunciation, uses, dosage guidelines, indications, and instructions on how and when to take it and when to avoid it.

The updated prescription information on Lorlatinib provides an overview of possible side effects, precautions, warnings, and storage tips.

You'll also find brand names used in india and internationally, along with pricing details. For further clarification, consult your healthcare provider.

Generic Name : Lorlatinib

Pronunciation : Lor LA ti nib

Trade Names/Brand Names of Lorlatinib

India :

Lorbrena

Overview of Lorlatinib

Lorlatinib is an anticancer drug that is used to treat metastatic non-small cell lung cancer (NSCLC).

Why is Lorlatinib Prescribed? (Indications)

Lorlatinib is indicated for the treatment of anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) which has been already treated by
• For metastatic disease, crizotinib and at least one other ALK inhibitor; or
• For metastatic disease,alectinibas the first ALK inhibitor therapy; or
• For metastatic disease, ceritinib as the first ALK inhibitor therapy.

When should Lorlatinib not be taken? (Contraindications)

•Along with Glucocorticoids, Rifampin, Carbamazepine, Phenobarbital and Phenytoin
• Breastfeeding

What is the dosage of Lorlatinib?

100mg should be taken once daily with or without food, until disease progression or unacceptable toxicity.
Tablet strength- 25mg and 100mg.

How should Lorlatinib be taken?

Swallow the tablets whole. If the tablets are not intact, broken or cracked, do not take them.
The dose of Lorlatinib should be taken at the same time every day.

Missed a Dose?

In case of a missed dose, take the missed dose only if the next dose is not scheduled within 4 hours. Do not take 2 doses at the same time.
If vomiting occurs after taking Lorlatinib, do not take an additional dose and continue with the next scheduled dose.

What are the warnings and precautions for Lorlatinib?

•Lorlatinib when given with a strong CYP3A inducer can increase the risk of serious hepatotoxicity. Discontinue strong CYP3A inducers before giving lorlatinib.

• Withhold and resume Lorlatininb at same or reduced dose or permanently discontinue Lorlatinib based on severity of CNS symptoms like seizures, hallucinations and changes in cognitive function, mood (including suicidal ideation), speech, mental status, and sleep.

• In case of hyperlipidemia, initiate or increase the dose of lipid-lowering agents. In case of atrioventricular block, withhold and resume Lorlatinib at same or reduced dose based on severity.

• In patients with suspected Interstitial Lung Disease/Pneumonitis, immediately stop Lorlatinib.

• Lorlatinib can cause fetal harm, hence females and males of reproductive age should use an effective non-hormonal method of contraception.

What are the side effects of Lorlatinib?

• Psychiatric- Mood effects
• Nervous disorder- sleep effects, speech effects, cognitive effects, headache, dizziness, peripheral neuropathy
• Respiratory- cough, shortness of breath
• Ocular- vision disturbances
• Gastrointestinal- Nausea, Vomiting, Diarrhea, Constipation
• Musculoskeletal- Joint pain, muscle pain, back pain, pain in extremity • Skin- Rash
• General- edema, weight gain, fatigue, fever
• Infections- Upper respiratory tract infections

What are the other precautions for Lorlatinib?

Prior to taking Lorlatinib, the patient needs to inform their healthcare provider about all the medical conditions, including-
• Episodes of seizures or depression
• High cholesterol levels
• Heart problems
• Lung or breathing problems
• are pregnant or plan to become pregnant as Lorlatinib can be harmful for the baby
• Breastfeeding. Do not breastfeed during treatment and for 7 days after the final dose.
The patient should inform the healthcare provider about all the medicines they take including, OTCs, vitamins, herbal supplements and prescription medicines.